Since ENCAVIR is primarily eliminated by the kidneys, co-administration of ENCAVIR with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of ENCAVIR or the co-administered drug. Monitor patients closely for adverse reactions when ENCAVIR is co-administered with such drugs.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
